Integra LifeSciences Reports Mixed 2025 Results, Guides to Modest 2026 Growth
Event summary
- Integra LifeSciences reported Q4 2025 revenues of $434.9M, down 1.7% YoY, with full-year 2025 revenues at $1.64B, up 1.5% YoY.
- GAAP net loss for 2025 was $(516.5)M, primarily due to a $511M goodwill impairment charge.
- 2026 revenue guidance is $1.66B–$1.70B, with adjusted EPS expected between $2.30–$2.40.
- Codman Specialty Surgical segment grew 2.7% YoY in Q4, while Tissue Technologies declined 12.8% YoY.
- Company implemented a simplified operating model to improve long-term margin improvement.
The big picture
Integra LifeSciences' mixed 2025 results reflect ongoing operational challenges and regulatory headwinds. The company's strategic focus on margin improvement and operational restructuring is critical amid a competitive medical technology landscape. The 2026 guidance suggests cautious optimism, contingent on successful execution of cost-saving initiatives and navigating regulatory uncertainties.
What we're watching
- Operational Efficiency
- The effectiveness of Integra's simplified operating model in driving margin improvement and cost savings.
- Regulatory Impact
- The potential financial impact of the Supreme Court ruling on tariffs and its implementation on Integra's 2026 guidance.
- Segment Performance
- Whether the Codman Specialty Surgical segment can sustain growth while addressing the decline in the Tissue Technologies segment.
Related topics